Means and methods for assessing increased peroxisomal proliferation

Patent metadata

Field	Value
Publication number	US-9304136-B2
Application number	US-201414152411-A
Country	US
Kind code	B2
Filing date	Jan 10, 2014
Priority date	May 28, 2008
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection including characteristic values of at least five metabolites, a data storage medium including data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

First claim

The invention claimed is:

1. A method for diagnosing a disorder associated with increased peroxisomal proliferation comprising:
(a) selecting a male or female subject suspected to suffer from increased peroxisomal proliferation, wherein said male or female is suspected to have been in contact with a compound capable of inducing peroxisomal proliferation;
(b) obtaining a blood sample that was taken from the male or female subject, wherein the blood sample contains one or more analytes;
(c) removing the cellular constituents from the blood sample using centrifugation to create a test sample;
(d) determining the amount of at least five of the following analytes Coenzyme Q10, 16-Methylheptadecanoic acid, 17-Methyloctadecanoic acid, Eicosatrienoic acid (C20:3), Threonine, Proline, Tyrosine, trans-4-Hydroxyproline from the test sample from the male subject, or the amount of at least five of the following analytes Pantothenic acid, Coenzyme Q9, Glycerol, Palmitic acid (C16:0), Linoleic acid (C18:cis[9,12]2), 14-Methylhexadecanoic acid, gamma-Linolenic acid (C18:cis[6,9,12]3), 16-Methylheptadecanoic acid, Threonic acid, Cytosine, Phosphatidylcholine (C18:0/C22:6) from the test sample from the female subject;
(e) comparing the amounts determined in step (d) to corresponding reference results, wherein the reference results comprise
(i) reference results obtained from one or more test samples derived from one or more subjects which has been brought into contact with Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate or Wy 14643,
(ii) reference results obtained from one or more test samples derived from one or more subjects which has not been brought into contact with Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate or Wy 14643,
(iii) reference results obtained from one or more test samples derived from one or more subjects which suffers from increased peroxisomal proliferation, or
(iv) reference results obtained from one or more test samples derived from one or more subjects known to not suffer from increased peroxisomal proliferation; and

(f) based on the comparison of step (e), diagnose the disorder by monitoring, confirmation, or classification of the disorder or its symptoms in the male or female subject.

2. The method of claim 1 , wherein said male or female subject has been brought into contact with a compound suspected to be capable of inducing increased peroxisomal proliferation.

3. The method of claim 2 , wherein said compound is at least one compound selected from the group consisting of: Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate, and Wy 14643.

4. The method of claim 1 , wherein said reference result is obtained from one or more test samples derived from (i) one or more subjects which suffers from increased peroxisomal proliferation; or (ii) one or more subjects which has been brought into contact with at least one compound selected from the group consisting of: Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate, and Wy 14643.

5. The method of claim 4 , wherein identical amounts for the analytes in the test sample and the reference result are indicative for increased peroxisomal proliferation.

6. The method of claim 1 , wherein said reference result is obtained from one or more test samples derived from (i) one or more subjects known to not suffer from increased peroxisomal proliferation; or (ii) one or more subjects which has not been brought into contact with at least one compound selected from the group consisting of: Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate, and Wy 14643.

7. The method of claim 6 , wherein amounts for the analytes which differ in the test sample in comparison to the reference result are indicative for increased peroxisomal proliferation.

8. The method of claim 1 , wherein indicative for increased peroxisomal proliferation are amounts of the analytes in comparison to the reference result of one or more subjects known to not suffer from increased peroxisomal proliferation which differ as follows: (i) in a test sample of a male: Coenzyme Q10 decreased, 16-Methylheptadecanoic acid decreased, 17-Methyloctadecanoic acid decreased, Eicosatrienoic acid (C20:3) increased, Threonine decreased, Proline decreased, Tyrosine decreased, trans-4-Hydroxyproline decreased; and (ii) in a test sample of a female subject: Pantothenic acid increased, Coenzyme Q9 increased, Glycerol increased, Palmitic acid (C16:0) increased, Linoleic acid (C18:cis[9,12]2) increased, 14-Methylhexadecanoic acid increased, gamma-Linolenic acid (C18:cis[6,9,12]3) decreased, 16-Methylheptadecanoic acid decreased, Threonic acid increased, Cytosine decreased, Phosphatidylcholine (C18:0/C22:6) decreased.

9. The method of claim 1 , wherein said increased peroxisomal proliferation results in a predisposition for at least one disorder or disease selected from the group consisting of: cancer, thyroid disorders, reproductive dysfunction, skeletal and cardiac myopathies, and dysfunction of the immune system.

10. The method of claim 1 , wherein said determining the amount of analytes comprises mass spectrometry (MS).

11. The method of claim 10 , wherein said mass spectrometry is liquid chromatography (LC)-MS or gas chromatography (GC)-MS.

12. The method of claim 11 , wherein the method is automated.

13. The method of claim 12 , wherein the method comprises computer assisted data processing.

14. The method of claim 1 , wherein said subject is a mammal.

15. A method of determining whether a subject suffers from peroxisomal proliferation by measuring the quantitative and/or qualitative composition of a subject's metabolome with respect to at least five analytes comprising:
(a) selecting a male or female subject suspected to suffer from increased peroxisomal proliferation;
(b) receiving a blood sample from the male or female subject;
(c) removing one or more cellular constituents, including one or more red and white blood cells, from the blood sample using centrifugation to create a plasma or serum test sample;
(d) determining the quantitative and/or qualitative composition of the subject's metabolome with respect to
(i) at least five of the following analytes: Coenzyme Q10, 16-Methylheptadecanoic acid, 17-Methyloctadecanoic acid, Eicosatrienoic acid (C20:3), Threonine, Proline, Tyrosine, trans-4-Hydroxyproline from the test sample from the male subject, or
(ii) at least five of the following analytes: Pantothenic acid, Coenzyme Q9, Glycerol, Palmitic acid (C16:0), Linoleic acid (C18:cis[9,12]2), 14-Methylhexadecanoic acid, gamma-Linolenic acid (C18:cis[6,9,12]3), 16-Methylheptadecanoic acid, Threonic acid, Cytosine, Phosphatidylcholine (C18:0/C22:6) from the test sample from the female subject

(e) determining based on comparing the quantitative and/or qualitative composition of a subject's metabolome to a reference metabolome whether the subject suffers from peroxisomal proliferation.

16. The method of claim 15 , wherein said male or female subject has been brought into contact with a compound suspected to be capable of inducing increased peroxisomal proliferation.

17. The method of claim 16 , wherein said compound is at least one compound selected from the group consisting of: Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate, and Wy 14643.

18. The method of claim 15 , wherein said determining the composition of the subject's metabolome comprises mass spectrometry (MS

Assignees

• Basf Se

Inventors

• Van Ravenzwaay Bennard
• Mellert Werner
• Fabian Eric
• Strauss Volker
• Walk Tilmann B
• Looser Ralf
• Leibold Edgar
• Kamp Hennicke
• Coelho Palermo Cunha Georgia
• Herold Michael Manfred
• Wiemer Jan C
• Prokoudine Alexandre

Classifications

• G01N2800/046

  Thyroid disorders · CPC title

• G01N33/68 Primary

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• G01N2800/24

  Immunology or allergic disorders · CPC title

• G01N33/92

  involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} · CPC title

• G01N33/6812

  Assays for specific amino acids · CPC title